Allulose Shows Promise for Weight Loss But Effects Remain Inconsistent
New rare sugar sweetener may reduce body fat and blood sugar, but research shows mixed results and potential digestive issues.
20 articles
New rare sugar sweetener may reduce body fat and blood sugar, but research shows mixed results and potential digestive issues.
A 20,000-person study finds IgG glycan patterns track biological aging, predict mortality, and shift toward youth with interventions.
NorthStrive Biosciences files a patent for EL-22, a myostatin-targeting probiotic designed to prevent muscle loss from GLP-1 drugs and aging.
Casein from dairy and wheat gluten dramatically reduce cholera bacteria colonization by disabling their key attack mechanism.
A 12-week study found Omada's wraparound GLP-1 program doubled fat loss and nearly tripled muscle preservation vs. controls.
Just 48 hours of eating mostly oatmeal dramatically reduced LDL cholesterol in people with metabolic syndrome, with benefits lasting weeks.
Glycans โ sugar molecules on proteins โ shift with stress, diet, and lifestyle, and may predict disease a decade before symptoms appear.
Metashape Pharma's MS 001 paired with semaglutide shows fat-selective weight loss and muscle preservation in preclinical mouse studies.
The FDA cleared Dexcom's Stelo CGM for children 2+, offering real-time glucose tracking without a prescription for young users.
NorthStrive Biosciences patents two muscle-preserving compounds targeting sarcopenia and GLP-1-related muscle loss in humans.
A 20,000-person study validates IgG glycans as aging biomarkers, with therapeutic plasma exchange reducing glycan age by 0.4 years per month.
Scientists discover harmful bacterial sugars in the gut trigger immune attacks that damage the brain in ALS and dementia patients.
Research finds the absorption enhancer in oral semaglutide tablets affects gut bacteria and inflammation markers beyond its intended role.
Satralizumab slashed relapses in MOGAD by 68% in the first-ever positive RCT for this demyelinating disease.
PCOS is being renamed polyendocrine metabolic ovarian syndrome (PMOS) to better reflect its complex, multi-system nature and reduce diagnostic delays.
Five large studies reveal dairy as the strongest dietary risk factor for Parkinson's disease, with potential brain cell damage mechanisms identified.
A new retrospective study finds GLP-1 use in early pregnancy reduces odds of gaining too little weight, but fetal safety questions remain.
OLX-07010, an oral drug targeting toxic tau proteins, advances toward Phase 1b Alzheimer's trials after securing $1.9M NIH safety grant.
A 12-week Omada Health study shows coaching and strength training dramatically improve fat loss and muscle retention alongside GLP-1 drugs.
Non-obese MASLD patients face 3x higher Alzheimer's mortality risk, plus Vitamin E shows liver benefits in new gastroenterology roundup.